{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T23:47:11Z","timestamp":1778197631032,"version":"3.51.4"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2016,2,15]],"date-time":"2016-02-15T00:00:00Z","timestamp":1455494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,2,15]],"date-time":"2016-02-15T00:00:00Z","timestamp":1455494400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1038\/leu.2016.30","type":"journal-article","created":{"date-parts":[[2016,2,15]],"date-time":"2016-02-15T07:41:19Z","timestamp":1455522079000},"page":"1753-1756","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Complete response to gemtuzumab ozogamicin in a patient with refractory mast cell leukemia"],"prefix":"10.1038","volume":"30","author":[{"given":"I","family":"Alvarez-Twose","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Mart\u00ednez-Barranco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Gotlib","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Garc\u00eda-Montero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J M","family":"Morgado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Jara-Acevedo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J D","family":"Merker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F J","family":"Pe\u00f1alver","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Matito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y","family":"Hou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"S\u00e1nchez-Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Mayado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Mollejo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"Escribano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Orfao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,2,15]]},"reference":[{"key":"BFleu201630_CR1","first-page":"291","volume-title":"World Health Organization (WHO) Classification of Tumours,","author":"P Valent","year":"2001","unstructured":"Valent P, Horny H-P, Li CY, Longley JB, Metcalfe DD, Parwaresch RM et al. Mastocytosis. In: Jaffe ES, Harris NL, Stein H, Vardiman JW (eds). World Health Organization (WHO) Classification of Tumours, vol. 1. IARC Press: Lyon, France, 2001, pp 291\u2013302."},{"key":"BFleu201630_CR2","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/S0145-2126(01)00038-8","volume":"25","author":"P Valent","year":"2001","unstructured":"Valent P, Horny HP, Escribano L, Longley BJ, Li CY, Schwartz LB et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res 2001; 25: 603\u2013625.","journal-title":"Leuk Res"},{"key":"BFleu201630_CR3","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1093\/annonc\/mdu047","volume":"25","author":"P Valent","year":"2014","unstructured":"Valent P, Sotlar K, Sperr WR, Escribano L, Yavuz S, Reiter A et al. Refined diagnostic criteria and classification of mast cell leukemia (MCL) and myelomastocytic leukemia (MML): a consensus proposal. Ann Oncol 2014; 25: 1691\u20131700.","journal-title":"Ann Oncol"},{"key":"BFleu201630_CR4","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1111\/j.1600-0609.2011.01598.x","volume":"86","author":"A Mital","year":"2011","unstructured":"Mital A, Piskorz A, Lewandowski K, Wasag B, Limon J, Hellmann A . A case of mast cell leukaemia with exon 9 KIT mutation and good response to imatinib. Eur J Haematol 2011; 86: 531\u2013535.","journal-title":"Eur J Haematol"},{"key":"BFleu201630_CR5","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1182\/blood.V124.21.636.636","volume":"124","author":"J Gotlib","year":"2014","unstructured":"Gotlib J, Kluin-Nelemans HC, George TI, Akin C, Sotar K, Hermine O et al. Midostaurin (PKC412) Demonstrates a High Rate of Durable Responses in Patients with Advanced Systemic Mastocytosis: Results from the Fully Accrued Global Phase 2 CPKC412D2201 Trial. Blood 2014; 124: 636.","journal-title":"Blood"},{"key":"BFleu201630_CR6","doi-asserted-by":"publisher","first-page":"3264","DOI":"10.1200\/JCO.2014.55.2018","volume":"32","author":"C Ustun","year":"2014","unstructured":"Ustun C, Reiter A, Scott BL, Nakamura R, Damaj G, Kreil S et al. Hematopoietic stem-cell transplantation for advanced systemic mastocytosis. J Clin Oncol 2014; 32: 3264\u20133274.","journal-title":"J Clin Oncol"},{"key":"BFleu201630_CR7","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.exphem.2006.09.008","volume":"35","author":"MT Krauth","year":"2007","unstructured":"Krauth MT, Bohm A, Agis H, Sonneck K, Samorapoompichit P, Florian S et al. Effects of the CD33-targeted drug gemtuzumab ozogamicin (Mylotarg) on growth and mediator secretion in human mast cells and blood basophils. Exp Hematol 2007; 35: 108\u2013116.","journal-title":"Exp Hematol"},{"key":"BFleu201630_CR8","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1111\/j.1365-2362.2007.01807.x","volume":"37","author":"P Valent","year":"2007","unstructured":"Valent P, Akin C, Escribano L, F\u00f6dinger M, Hatmann K, Brockow K et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest 2007; 37: 435\u2013453.","journal-title":"Eur J Clin Invest"},{"key":"BFleu201630_CR9","doi-asserted-by":"publisher","first-page":"3197","DOI":"10.1182\/blood.V97.10.3197","volume":"97","author":"VH van Der Velden","year":"2001","unstructured":"van Der Velden VH, Te Marvelde JG, Hoogeveen PG, Bernstein ID, Houtsmuller AB, Berger MS et al. Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells. Blood 2001; 97: 3197\u20133204.","journal-title":"Blood"},{"key":"BFleu201630_CR10","first-page":"1493","volume":"149","author":"A Orfao","year":"1996","unstructured":"Orfao A, Escribano L, Villarrubia J, Velasco JL, Cerver\u00f3 C, Ciudad J et al. Flow cytometric analysis of mast cells from normal and pathological human bone marrow samples. Identification and enumeration. Am J Pathol 1996; 149: 1493\u20131499.","journal-title":"Am J Pathol"},{"key":"BFleu201630_CR11","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1111\/j.1365-2141.2010.08095.x","volume":"149","author":"S Amadori","year":"2010","unstructured":"Amadori S, Suciu S, Selleslag D, Stasi R, Alimena G, Baila L et al. Randomized trial of two schedules of low-dose gemtuzumab ozogamicin as induction monotherapy for newly diagnosed acute myeloid leukaemia in older patients not considered candidates for intensive chemotherapy. A phase II study of the EORTC and GIMEMA leukaemia groups (AML-19). Br J Haematol 2010; 149: 376\u2013382.","journal-title":"Br J Haematol"},{"key":"BFleu201630_CR12","first-page":"S207","volume":"119","author":"DK Jeong","year":"2007","unstructured":"Jeong DK, Fauman K, Ross C, Akin C, Mody R . Successful treatment of systemic mastocytosis associated with AML-M2, t (8: 21) in a child using MRC-based AML chemotherapy along with gemtuzumab. J Allergy Clin Immunol 2007; 119, (Suppl 1) S207 (abstract 814).","journal-title":"J Allergy Clin Immunol"},{"key":"BFleu201630_CR13","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/S0145-2126(02)00168-6","volume":"27","author":"P Valent","year":"2003","unstructured":"Valent P, Akin C, Sperr WR, Escribano L, Arock M, Horny HP et al. Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria. Leuk Res 2003; 27: 635\u2013641.","journal-title":"Leuk Res"},{"key":"BFleu201630_CR14","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1182\/blood-2012-09-458521","volume":"121","author":"J Gotlib","year":"2013","unstructured":"Gotlib J, Pardanani A, Akin C, Reiter A, George T, Hermine O et al. International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis. Blood 2013; 121: 2393\u20132401.","journal-title":"Blood"},{"key":"BFleu201630_CR15","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","volume":"368","author":"Cancer Genome Atlas Research Network","year":"2013","unstructured":"Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 2013; 368: 2059\u20132074.","journal-title":"N Engl J Med"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu201630.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu201630","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu201630.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T16:21:57Z","timestamp":1648743717000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu201630"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,15]]},"references-count":15,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["BFleu201630"],"URL":"https:\/\/doi.org\/10.1038\/leu.2016.30","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,15]]},"assertion":[{"value":"15 February 2016","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}